Specific targeted therapy of chronic myelogenous leukemia with imatinib

Pharmacological Reviews

Volumn 55, Issue 3, 2003, Pages 401-423

  Deininger, Michael W N ^a   Druker, Brian J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ADAPHOSTIN; ALPHA INTERFERON; ARSENIC TRIOXIDE; BCR ABL PROTEIN; CHIMERIC PROTEIN; CYTOTOXIC AGENT; GELDANAMYCIN; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NSC 860410; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TYRPHOSTIN; UNCLASSIFIED DRUG;

ALLOGENEIC RESTRICTION; ANIMAL EXPERIMENT; APOPTOSIS; ARTHRALGIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE PAIN; CANCER STAGING; CELL LINE; CELL PROLIFERATION; CHROMOSOME 22; CHROMOSOME 9; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; EDEMA; ENZYME ACTIVITY; ENZYME ASSAY; EXTRACELLULAR MATRIX; FLUID RETENTION; FUSION GENE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKEMIA REMISSION; LIVER TOXICITY; MYALGIA; NEUTROPENIA; ONCOGENE; PATHOGENESIS; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; STEM CELLS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0041466445     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: 10.1124/pr.55.3.4     Document Type: Review

References (181)

1. Abelson HT and Rabstein LS (1970) Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res 30:2213-2222.
2. Afar DE, McLaughlin J, Sherr CJ, Witte ON, and Roussel MF (1995) Signaling by ABL oncogenes through cyclin D1. Proc Natl Acad Sci USA 92:9540-9544.
3. Al Ali HK, Leiblein S, Kovacs I, Hennig E, Niederwieser D, and Deininger MW (2002) CML with an E1a3 BCR-ABL fusion: rare, benign and a potential diagnostic pitfall. Blood 100:1092-1093.
4. Amos TA, Lewis JL, Grand FH, Gooding RP, Goldman JM, and Gordon MY (1995) Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br J Haematol 91: 387-393.
5. Anafi M, Gazit A, Zehavi A, Ben Neriah Y, and Levitzki A (1993) Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 82:3524-3529.
6. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, and Brondum-Nielsen K (2002) Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 16:1390-1393.
7. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, et al. (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481-487.
8. Baccarani M, Rosti G, de Vivo A, Bonifazi F, Russo D, Martinelli G, Testoni N, Amabile M, Fiacchini M, Montefusco E, et al. (2002) A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 99:1527-1535.
9. Barila D and Superti Furga G (1998) An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet 18:280-282.
10. Bartram CR, de Mein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson Smith MA, Davies T, and Stone M (1983) Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature (Lond) 306:277-280.
11. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y, Barlow C, Baltimore D, Wynshaw Boris A, Kastan MB, et al. (1997) Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature (Lond) 387:516-519.
12. 2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86:1148-1158.
13. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, and Jones RJ (1994) Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83:2038-2044.
14. Bennett JH (1845) Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood. Edinb Med Surg J 64:413-423.
15. Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB and Kantarjian H (1998) Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 4:1661-1672.
16. Blanke CD, Eisenberg BL, and Heinrich MC (2001) Gastrointestinal stromal tumors. Curr Treat Options Oncol 2:485-491.
17. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, Hehlmann R, Hochhaus A, Shepherd PC, Steegmann JL, et al. (2001) Chronic myeloid leukemia and interferon-alpha; a study of complete cytogenetic responders. Blood 98:3074-3081.
18. Bornhauser M, Kiehl M, Siegert W, Schetelig J, Hertenstein B, Martin H, Schwerdtfeger R, Sayer HG, Runde V, Kroger N, et al. (2001) Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. Br J Haematol 115:119-124.
19. Bose S, Deininger M, Gora-Tybor J, Goldman JM, and Melo JV (1998) The presence of BCR-ABL fusion genes in leukocytes of normal individuals: implications for the assessment of minimal residual disease. Blood 92:3362-3367.
20. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, and Lydon NB (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100-104.
21. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Regenass U, and Lydon NB (1995) Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 92:2558-2562.
22. Bumm T, Muller C, Al Ali HK, Krohn K, Shepherd P, Schmidt E, Leiblein S, Franke C, Hennig E, Friedrich T, et al. (2003) Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101:1941-1949.
23. Canitrot Y, Lautier D, Laurent G, Frechet M, Ahmed A, Turhan AG, Salles B, Cazaux C, and Hoffmann JS (1999) Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene 18:2676-2680.
24. Carlo Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, Bonati A, Almici C, Sammarelli G, Savoldo B, Rizzo MT, et al. (1996) Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Blood 88:3091-3100.
25. Carroll M, Ohno Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, and Druker B (1997) CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins. Blood 90:4947-4952.
26. Cervantes F, Hernandez-Boluda JC, Ferrer A, Cid J, and Montserrat E (1999) The changing profile of ph-positive chronic myeloid leukemia at presentation: possible impact of earlier diagnosis on survival. Haematologica 84:324-327.
27. Chen G, Yuan SS, Liu W, Xu Y, Trujillo K, Song B, Cong F, Goff SP, Wu Y, Arlinghaus R, et al. (1999) Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem 274:12748-12752.
28. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, et al. (2003). A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201-1214.
29. Corbin AS, Buchdunger E, Pascal F, and Druker BJ (2002) Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 277: 32214-32219.
30. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, and Deininger MW (2003) Several bcr-abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101:4611-4614.
31. Corso A, Lazzarino M, Morra E, Merante S, Astori C, Bernasconi P, Boni M, and Bernasconi C (1995) Chronic myelogenous leukemia and exposure to ionizing radiation - a retrospective study of 443 patients. Ann Hematol 70:79-82.
32. Cortez D, Stoica G, Pierce JH, and Pendergast AM (1996) The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene 13:2589-2594.
33. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, and Goldman JM (1993) Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82:1929-1936.
34. Dai Z and Pendergast AM (1995) Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev 9:2569-2582.
35. Daley GQ, Van Etten RA, and Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (Wash DC) 247:824-830.
36. Dan S, Naito M, and Tsuruo T (1998) Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148, Cell Death Differ 5:710-715.
37. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. (2002) Mutations of the BRAF gene in human cancer. Nature (Lond) 417:949-954.
38. Dazzi F and Goldman J (1999) Donor lymphocyte infusions. Curr Opin Hematol 6:394-399.
39. Deininger M, Goldman JM, Lydon NB, and Melo JV (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood 90:3691-3698.
40. Deininger MW, Bose S, Gora-Tybor J, Yan XH, Goldman JM, and Melo JV (1998) Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation. Cancer Res 58:421-425.
41. Deininger MW, Goldman JM, and Melo JV (2000a) The molecular biology of chronic myeloid leukemia. Blood 96:3343-3356.
42. Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, and Melo JV (2000b) BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res 60:2049-2055.
43. Deininger MWN, Schleuning M, Sayer HG, Greinix H, Fischer T, Olavarria E, Maziarz RT, Martinez J, and Niederwieser D (2002) Allografting after imatinib therapy: no evidence for increased transplant-related mortality and favorable results in patients transplanted in remission. A retrospective study by the EBMT. Blood 100:783a.
44. Diekmann D, Brill S, Garrett MD, Totty N, Hsuan J, Monfries C, Hall C, Lim L, and Hall A (1991) Bcr encodes a GTPase-activating protein for p21rac. Nature (Lond) 351:400-402.
45. Djaldetti M, Padeh B, Pinkhas J, and De Vries A (1966) Prolonged remission in chronic myeloid leukemia after one course of busulfan. Blood 27:103-109.
46. Dorsey JF, Jove R, Kraker AJ, and Wu J (2000) The pyrido[2,3-d] pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 60:3127-3131.
47. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, and Talpaz M (2001b) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042.
48. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, et al. (2001a) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037.
49. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, and Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566.
50. Elmberger PG, Lozano MD, Weisenburger DD, Sanger W, and Chan WC (1995) Transcripts of the Npm-Alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease and reactive lymphoid lesions. Blood 86:3517-3521.
51. Etienne G, Cony-Makhoul P, and Mahon FX (2002) Imatinib mesylate and gray hair. N Engl J Med 347:446.
52. Feinstein E, Cimino G, Gale RP, Alimena G, Berthier R, Kishi K, Goldman J, Zaccaria A, Berrebi A, and Canaani E (1991) p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA 88:6293-6297.
53. Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, di Nicola M, Biondi A, Corneo GM, Belotti D, et al. (1997) Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 23:380-394.
54. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, and Butterfield JH (2002) Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359:1577-1578.
55. Gordon MY, Dowding CR, Riley GP, Goldman JM, and Greaves MF (1987) Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature (Lond) 328:342-344.
56. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, and Sawyers CL (2002) BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 100:3041-3044.
57. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, and Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (Wash DC) 293:876-880.
58. Gotoh A, Miyazawa K, Ohyashiki K, Tauchi T, Boswell HS, Broxmeyer HE, and Toyama K (1995) Tyrosine phosphorylation and activation of focal adhesion kinase (P125FAK) by BCR-ABL oncoprotein. Exp Hematol (Copenh) 23:1153-1159.
59. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, and Holyoake TL (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319-325.
60. Gratwohl A, Baldomero H, Horisberger B, Schmid C, Passweg J, and Urbano-Ispizua A (2002) Current trends in hematopoietic stem cell transplantation in Europe. Blood 100:2374-2386.
61. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, and Grosveld G (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93-99.
62. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, et al. (1997) Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 337:223-229.
63. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb RF, et al. (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962-968.
64. Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J, and Superti-Furga G (2003) A myristoyl/phorphotyrosine switch regulates c-Abl. Cell 112:845-857.
65. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, and Ansari H (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Working Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850-858.
66. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Loffler H, Hochhaus A, Heinze B, et al. (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 84:4064-4077.
67. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, and Groffen J (1990) Acute leukaemia in bcr/abl transgenic mice. Nature (Lond) 344:251-253.
68. Heyssel R, Brill B, and Woodbury L (1960) Leukemia in Hiroshima bomb survivors. Blood 15:313.
69. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, et al. (2002) Molecular and, chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190-2196.
70. Hoepfl J, Miething C, Grundler R, Gotze KS, Peschel C, and Duyster J (2002) Effects of imatinib on bone marrow engraftment in syngeneic mice. Leukemia 16:1584-1588.
71. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, and Bhatia R (2002) Imatinib mesylate (STI571) inhibits growth primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99:3792-3800.
72. Hoover RR, Mahon FX, Melo JV, and Daley GQ (2002) Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 100:1068-1071.
73. Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS, Wang WS, Yen CC, and Chen PM (2002) Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 117:620-622.
74. Ilaria RL Jr and Van Etten RA (1995) The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells. Blood 86:3897-3904.
75. Italian Cooperative Study Group on CML (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med 330:820-825.
76. Jiang X, Lopez A, Holyoake T, Eaves A, and Eaves C (1999) Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci USA 96:12804-12809.
77. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, et al. (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056.
78. Johansson B, Fioretos T, and Mitelman F (2002) Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107:76-94.
79. Jonuleit T, Peschel C, Schwab R, van der Kuip H, Buchdunger E, Fischer T, Huber C, and Aulitzky WE (1998) Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors. Br J Haematol 100:295-303.
80. Kaneta Y, Kagami Y, Katagiri T, Tsunoda T, Jin-nai I, Taguchi H, Hirai H, Ohnishi K, Ueda T, Emi N, et al. (2002) Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide CDNA microarray analysis. Jpn J Cancer Res 93:849-856.
81. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, and Furukawa Y (2001) In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97:1999-2007.
82. Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, Koller C, Feldman E, and Talpaz M (1992) Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol 10:772-778.
83. Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, McCredie EB, and Freireich EJ (1987) Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 83:445-454.
84. Kantarjian HM, O'Brien SM, Keating M, Beran M, Estey E, Giralt S, Kornblau S, Rios MB, de Vos D, and Talpaz M (1997) Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 11: 1617-1620.
85. Kantarjian HM, Vellekoop L, McCredie KB, Keating MJ, Hester J, Smith T, Barlogie B, Trujillo J, and Freireich EJ (1985) Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol 3:192-200.
86. Kasper B, Fruehauf S, Schiedlmeier B, Buchdunger E, Ho AD, and Zeller WJ (1999) Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors. Cancer Chemother Pharmacol 44:433-438.
87. Kaur G, Gazit A, Levitzki A, Stowe E, Cooney DA, and Sausville EA (1994) Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs 5:213-222.
88. Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, Williams I, Amaral SM, Curley DP, Duclos N, et al. (2002) CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 1:421-432.
89. Kharbanda S, Pandey P, Jin S, Inoue S, Bharti A, Yuan ZM, Weichselbaum R, Weaver D, and Kufe D (1997) Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature (Lond) 386:732-735.
90. Klejman A, Rushen L, Morrione A, Slupianek A, and Skorski T (2002a) Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 21:5868-5876.
91. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupiariek A, Wilson M, Smithgall TE, and Skorski T (2002b) The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO (Eur Mol Biol Organ) J 21:5766-5774.
92. Koleske AJ, Gifford AM, Scott ML, Nee M, Bronson RT, Miczek KA, and Baltimore D (1998) Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron 21:1259-1272.
93. Kovalenko M, Ronnstrand L, Heldin CH, Loubtchenkov M, Gazit A, Levitzki A, and Bohmer FD (1997) Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry 36:6260-6269.
94. Lange T, Gunther C, Kohler T, Krahl R, Musiol S, Leiblein S, Al Ali HK, van Hoomissen I, Niederwieser D, and Deininger MW (2003) High levels of BAX, low levels of MRP-1 and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood 101:2152-2155.
95. La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, and Druker BJ (2002c) Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 62:7149-7153.
96. La Rosee P, Johnson K, O'Dwyer ME, and Druker BJ (2002a) In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol (Copenh) 30:729-737.
97. La Rosee P, O'Dwyer ME, and Druker BJ (2002b) Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia 16:1213-1219.
98. le Coutre, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, and Gambacorti-Passerini C (1999) In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 91:163-168.
99. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, and Gambacorti-Passerini C (2000) Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95:1758-1766.
100. Lewis JM and Schwartz MA (1998) Integrins regulate the association and phosphorylation of paxillin by c-Abl. J Biol Chem 273:14225-14230.
101. Li S, Gillessen S, Tomasson MH, Dranoff G, Gilliland DG, and Van Etten RA (2001) Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. Blood 97:1442-1450.
102. Lindahl P, Johansson BR, Leveen P, and Betsholtz C (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science (Wash DC) 277:242-245.
103. Lugo TG, Pendergast AM, Muller AJ, and Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (Wash DC) 247:1079-1082.
104. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, and Melo JV (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96:1070-1079.
105. Marais R, Light Y, Paterson HF, and Marshall CJ (1995) Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO (Eur Mol Biol Organ) J 14:3136-3145.
106. Marktel S, Bua M, Marin D, Chase A, Udom C, Armstrong L, Apperley JF, Olavarria E, and Goldman JM (2001) Emergence of additional chromosomal abnormalities following treatment with STI571 (imatinib mesylate) for Philadelphia positive chronic myeloid leukemia in chronic phase (Abstract). Blood 98:217a.
107. Marley SB, Deininger MW, Davidson RJ, Goldman JM, and Gordon MY (2000) The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol (Copenh) 28:551-557.
108. Maru Y and Witte ON (1991) The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell 67:459-468.
109. Mauro MJ, Kurilik G, Balleisen S, O'Dwyer ME, Reese SF, and Druker BJ (2001) Myeloid growth factors for neutropenia during imatinib mesylate (STI571) therapy for CML: preliminary evidence of safety and efficacy. Blood 98:139a.
110. Mayer BJ and Baltimore D (1994) Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase. Mol Cell Biol 14:2883-2894.
111. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, et al. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390-3400.
112. McWhirter JR, Galasso DL, and Wang JY (1993) A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 13:7587-7595.
113. McWhirter JR and Wang JY (1993) An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO (Eur Mol Biol Organ) J 12:1533-1546.
114. Melo JV, Gordon DE, Cross NC, and Goldman JM (1993) The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 81:158-165.
115. Melo JV, Myint H, Galton DA, and Goldman JM (1994) P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 8:203-211.
116. Million RP and Van Etten RA (2000) The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood 96:664-670.
117. Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, Kottke TJ, Narayanan VL, Litzow MR, Griffin JD, Sausville EA, et al. (2002) Effects of the Bcr/Abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99:664-671.
118. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, and Kuriyan J (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62:4236-4243.
119. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, and Kuriyan J (2003) Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112:859-871.
120. Neumann E (1870) Ein Fall Von Leukämie Mit Erkrankung Des Knochenmarks. Archive der Heilkunde.
121. Nowell P and Hungerford D (1960) A minute chromosome in human chronic granulocytic leukemia. Science (Wash DC) 132:1497.
122. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004.
123. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, and Druker BJ (1994) Crk1 is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 269:22925-22928.
124. O'Dwyer ME, Gatter K, Loriaux M, Druker B, Olsen JH, Lawce H, Mauro MJ, Maziarz RT, and Braziel RM (2003) The demonstration of clonal abnormalities in Philadelphia chromosome negative cells following imatinib mesylate induced major cytogenetic responses in patients with chronic myeloid leukemia. Leukemia 17:481-487.
125. Okabe M, Uehara Y, Miyagishima T, Itaya T, Tanaka M, Kuni Eda Y, Kurosawa M, and Miyazaki T (1992) Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth. Blood 80:1330-1338.
126. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, Aker M, Naparstek E, Nagler A, and Slavin S (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101:441-445.
127. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA, et al. (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100:1965-1971.
128. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, Meloni G, Saglio G, Salvatore F, and Rotoli B (1996) Neutrophilic chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 88:2410-2414.
129. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, and Wiedemann LM (1995) The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res 55:3438.
130. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, Pendergast AM, Bronson R, Aster JC, Scott ML, et al. (1998) Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92:3780-3792.
131. Perkins C, Kim CN, Fang G, and Bhalla KN (2000) Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 95:1014-1022.
132. Peters DG, Hoover RR, Gerlach MJ, Koh EY, Zhang H, Choe K, Kirschmeier P, Bishop WR, and Daley GQ (2001) Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 97:1404-1412.
133. Petzer AL, Eaves CJ, Lansdorp PM, Ponchio L, Barnett MJ, and Eaves AC (1996) Characterization of primitive subpopulation of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood 88:2162-2171.
134. Reckmann AH, Fischer T, and Peng B (2002) Effect of food on STI571 (Glivec) pharmacokinetics and bioavailability. Proc Am Soc Clin Oncol 20:1223a.
135. Ricci C, Scappini B, Divoky V, Gatto S, Onida F, Verstovsek S, Kantarjian HM, and Beran M (2002) Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res 62:5995-5998.
136. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, Fenaux P, and Preudhomme C (2002) Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571 and they can pre-exist to the onset of treatment. Blood 100:1014-1018.
137. Ron D, Zannini M, Lewis M, Wickner RB, Hunt LT, Graziani G, Tronick SR, Aaronson SA, and Eva A (1991) A region of proto-dbl essential for its transforming activity shows sequence similarity to a yeast cell cycle gene, CDC24 and the human breakpoint cluster gene, bcr. New Biol 3:372-379.
138. Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, and Van Etten RA (2002) Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 99:10700-10705.
139. Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (Lond) 243:290-293.
140. Salgia R, Li JL, Lo SH, Brunkhorst B, Kansas GS, Sobhany ES, Sun Y, Pisick E, Hallek M, Ernst T, et al. (1995) Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem 270:5039-5047.
141. Savage DG and Goldman JM (1997) Allografting for chronic myeloid leukemia. Curr Opin Hematol 4:369-376.
142. Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330-1340.
143. Sawyers CL, Callahan W, and Witte ON (1992) Dominant negative MYC blocks transformation by ABL oncogenes. Cell 70:901-910.
144. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, et al. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530-3539.
145. Sawyers CL, McLaughlin J, Goga A, Havlik M, and Witte O (1994) The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell 77:121-131.
146. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, and Kuriyan J (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (Wash DC) 289:1938-1942.
147. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Loffler H, Sauerland CM, Serve H, Buchner T, et al. (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100:59-66.
148. Schwartzberg PL, Stall AM, Hardin JD, Bowdish KS, Humaran T, Boast S, Harbison ML, Robertson EJ, and Goff SP (1991) Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell 65:1165-1175.
149. Sexl V, Piekorz R, Moriggl R, Rohrer J, Brown MP, Bunting KD, Rothammer K, Roussel MF, and Ihle JN (2000) Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood 96:2277-2283.
150. Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T, Hobson K, Gatei M, Zhang N, Watters D, et al. (1997) Interaction between ATM protein and c-Abl in response to DNA damage. Nature (Lond) 387:520-523.
151. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, and Sawyers CL (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125.
152. Shi Y, Alin K, and Goff SP (1995) Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, duppresses v-abl transforming activity. Genes Dev 9:2583-2597.
153. Shiotsu Y, Neckers LM, Wortman I, An WG, Schulte TW, Soga S, Murakata C, Tamaoki T, and Akinaga S (2000) Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 96:2284-2291.
154. Shtivelman E, Lifshitz B, Gale RP, Roe BA, and Canaani E (1986) Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 47:277-284.
155. Sill H, Goldman JM, and Cross NC (1995) Homozygous deletions of the P16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 85:2013-2016.
156. Sillaber C, Gesbert F, Frank DA, Sattler M, and Griffin JD (2000) STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 95:2118-2125.
157. Skorski T, Kanakaraj P, Nieborowska Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, and Calabretta B (1995) Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86:726-736.
158. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, et al. (1984) Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63:789-799.
159. Takedam N, Shibuya M, and Maru Y (1999) The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein. Proc Natl Acad Sci USA 96:203-207.
160. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, and Gutterman JU (1991) Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 114:532-538.
161. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, et al. (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928-1937.
162. Thiesing JT, Ohno-Jones S, Kolibaba KS, and Druker BJ (2000) Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 96:3195-3199.
163. Topaly J, Zeller WJ, and Fruehauf S, (2001) Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 15:342-347.
164. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, and Mulligan RC (1991) Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65:1153-1163.
165. Uehara Y, Murakami Y, Mizuno S, and Kawai S (1988) Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A. Virology 164:294-298.
166. Van Etten RA (1999) Cycling, stressed-out and nervous: cellular functions of c-abl. Trends Cell Biol 9:179-186.
167. Van Kaick G, Wesch H, Luhrs H, Liebermann D, and Kaul A (1991) Neoplastic diseases induced by chronic alpha-irradiation-epidemiological, biophysical and clinical results of the German Thorotrast Study. J Radiat Res Tokyo 32 (Suppl 2):20-33.
168. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, et al. (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421-1423.
169. Virchow R (1845) Weisses blut. Frorieps Notizen 36:151-156
170. von Bubnoff N, Schneller F, Peschel C, and Duyster J (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359:487-491
171. Voncken JW, van Schaick H, Kaartinen V, Deemer K, Coates T, Landing B, Pattengale P, Dorseiul O, Bokoch GM, Groffen J, et al. (1995) Increased neutrophil respiratory burst in bcr-null mutants. Cell 80:719-728.
172. Warmuth M, Bergmann M, Priess A, Hauslmann K, Emmerich B, and Hallek M (1997) The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem 272:33260-33270.
173. Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW, Buchdunger E, Forster K, Moarefi I, and Hallek M (2003) Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 101:664-672.
174. Wassmann B, Klein SA, Scheuring U, Pfeifer H, Martin H, Gschaidmeier H, Hoelzer D, and Ottmann OG (2001) Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. Bone Marrow Transplant 28:721-724.
175. Weisberg E and Griffin JD (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 95:3498-3505.
176. Wen ST and Van ER (1997) The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev 11:2456-2467.
177. Wertheim JA, Forsythe K, Druker BJ, Hammer D, Boettiger D, and Pear WS (2002) BCR-ABL-induced adhesion defects are tyrosine kinase-independent. Blood 99: 4122-4130.
178. Wolff NC and Ilaria RL Jr (2001) Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 98:2808-2816.
179. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, and Grant S (2002) Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 62:188-199.
180. Yuan ZM, Huang Y, Ishiko T, Kharbanda S, Weichselbaum R, and Kufe D (1997) Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase. Proc Natl Acad Sci USA 94:1437-1440.
181. Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, Kharbanda S, Wang R, Sung P, Shinohara A, Weichselbaum R, et al. (1998) Regulation of Rad51 function by c-Abl in response to DNA damage. J Biol Chem 273:3799-3802.